Frame guidelines on thalassemia treatment: SC to Centre
New Delhi: The Supreme Court asked the Centre to come up with guidelines for providing treatment to patients suffering from Thalassemia within four weeks.
Thalassemia, a genetic blood disorder, is usually characterised by abnormal production of haemoglobin in the body and the abnormality results in improper oxygen transport and destruction of red blood cells.
It has wide-ranging effects on the body such as iron overload, bone deformities, and in some cases, heart ailments.
A bench, comprising Chief Justice Dipak Misra and Justices A M Khanwilkar and D Y Chandrachud, asked the Centre to file "requisite guidelines" for providing treatment to patients suffering from Thalassemia within four weeks.
The bench posted the public interest litigation (PIL) for further hearing on March 12.
The court issued the directive while hearing the petition filed by Reepak Kansal. The petition claimed that the disease has no cure and people living with Thalassemia require regular blood transfusion as an effective measure to prolong life.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.